Breaking News: APLS – Market Insights, Analysis & Latest Updates

APLS

Apellis Pharmaceuticals shares surge following Astellas Pharma’s FDA setback

Apellis Pharmaceuticals' shares rose 16.44% after the FDA delayed a rival's drug approval, enhancing Syfovre's competitive advantage with its flexible dosing for geographic atrophy treatment.

investing.com • 19/11/2024 - 17:45 PM

APLS

Earnings call: Apellis Pharmaceuticals Q3 2024 results show promise

Apellis Pharmaceuticals reported Q3 2024 financial results, highlighting revenue growth and future outlook for SYFOVRE and EMPAVELI while expressing optimism despite slight revenue declines.

investing.com • 07/11/2024 - 08:20 AM

APLS

Apellis shares plunge 13% on wider-than-feared Q3 loss, revenue miss

Apellis Pharmaceuticals' Q3 earnings fell short, leading to a 13.48% stock drop. Revenue was below estimates despite growth in SYFOVRE sales compared to last year.

investing.com • 05/11/2024 - 12:19 PM

Greed and Fear Index

Note: The data is for reference only.

Greed

Apellis Pharmaceuticals shares surge following Astellas Pharma’s FDA setback

Earnings call: Apellis Pharmaceuticals Q3 2024 results show promise

Apellis shares plunge 13% on wider-than-feared Q3 loss, revenue miss

Currency